Drug Trial Radar · NCT06649942
A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Oct 1, 2024
Primary completion
Mar 24, 2025
Study completion Mar 24, 2025
Sponsor
- Lead sponsor
- Kaken PharmaceuticalIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Oct 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, single-center, randomized, single-blind (participants are blinded), placebo controlled, four-way cross over TQT study (4×4 Williams square design) to investigate the effect of KP-001 on the QTc interval using open-label moxifloxacin as an active control, in adult healthy volunteers. KP-001 and placebo (dry syrup) will be administered in blinded manner to participants, and the moxifloxacin (tablet) will be administered in open-label manner.Total duration of study participation for each participant is approximately 8 weeks. Cardiodynamic ECG evaluations will be performed at separate locations and cardiodynamic ECG evaluators will be blinded to treatment group analyzed, ie, blinded to each of the study interventions including moxifloxacin.
Conditions
- Healthy Volunteers - Male and Female
Interventions
KP-001Drug
KP-001 100 mg + placebo
KP-001Drug
KP-001 400 mg
Moxifloxacin 400 mgDrug
moxifloxacin 400 mg tablet
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Largest time-matched placebo-corrected change from baseline in QTcF (ΔΔQTcF) collected in a 24-hour period after KP-001 single dosingTime frame: Before dosing (Baseline) through 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel Early Phase Clinical Unit - Los Angeles
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.